News from external sources

200 EUR discount for OCC members: BIOEurope Spring® 2017

BIOEurope Spring 2017 — 11 th International Partnering Conference
Where the global biotech industry comes to partner

BIOEurope Spring is the springtime counterpart to EBD Group’s flagship conference, BIOEurope , and continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s sophisticated, webbased partnering system, partneringONE ® , the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative startups.

Venue:
CCIB Convention Centre
Willy Brandt Square 1114
08019 Barcelona, Spain

Date: March 20–22, 2017

Website: https://ebdgroup.knect365.com/bioeurope-spring/

The members of the Oslo Cancer Cluster have the opportunity to obtain 200 EUR discount on the registration fee. To receive the discount code, please contact Jutta Heix (or) Gupta Udatha.

gu-jh

 

20% discount for OCC members: NORDIC PRECISION MEDICINE FORUM 2017

The Nordic Countries represent a unique opportunity when it comes to healthcare; boasting a wealth of data, some of the most advanced HealthTech, and being host to world leading biotech and pharma companies and universities. As such it is little surprise that the precision medicine revolution is creating such a buzz; disruptive technology, a strong economic setting and decades of social and health data collection are coming together to create the perfect storm for the future of healthcare in the region.

It is widely accepted that for the promise of precision medicine to become a reality we must work together; sharing data and research via a multi-disciplinary approach as well as cross border collaboration.

Nordic Precision Medicine Forum will bring together those at the very forefront of precision medicine from biologists, physicians and technology developers to data scientists, patient groups, governments and more. We hope you can join the forum in Copenhagen on 26 April 2017.

logo2

The members of the Oslo Cancer Cluster have the opportunity to obtain 20% discount on the registration fee. To receive the discount code, please contact Jutta Heix (or) Gupta Udatha.

gu-jh

Career Day RealKarriere at UiO in February 2017

RealKarriere is the Career Day for the The Faculty of Mathematics and Natural Sciences at University in Oslo. In 2017 the Career day will be arranged on February 9th 2017. Find more information below in Norwegian or reach out to Oda Felix Sønslien  for more info or info in English.

 

RealKarriere er en nettverksdag for det Matematisk-Naturvitenskapelige fakultet ved Universitet i Oslo. Målet med dagen er å øke kontakten mellom arbeidslivet og fremtidens talenter innen teknologi- og realfag.

Bak denne dagen sitter en arbeidsgruppe bestående av studenter innen ulike fagområder og ansatte ved Universitetet. Målgruppa er hele det Matematisk-Naturvitenskapelige fakultet som består av studieprogram som dekker det meste av teknologi-og realfag. Dette er altså en flott mulighet for profilering av dere som bedrift, og til å plukke opp de dyktigste studentene! For mer informasjon se nettsiden.

 

Profileringsmuligheter

  • 2 minutters presentasjon for studentene på start av dagen (GRATIS)
  • Temapresentasjon på 20 minutter (5000,-)
  • Speed-intervju (3000,-)
  • Stor stand, 3 meter (10.000,-)
  • Liten stand, 2 meter (6000,-)
  • Snapchat og instagram “take over” (1000,-)

Prisene er eksl. Moms og inkluderer matservering samt eget pauserom for bedriftene.

Alle bedrifter som melder seg på vil få tilbud om en 2 minutters presentasjon på starten av dagen, dette vil hjelpe dere å hente relevante studenter til deres stand. Vi tilbyr også større presentasjoner på 20 minutter; her vil dere kunne velge et tema som vi vil profilere ekstra på sosiale medier opp i mot dagen.

Dere kan velge å ta over vår Snapchat og Instagram konto for en dag, der dere for eksempel kan vise frem en arbeidsdag hos deres bedrift.

Dere kan også velge å kjøre et speed-intervju, hvor dere selv plukker ut kandidatene dere ønsker å intervjue.

Påmeldingsskjema finner dere.
Kontakt:
Oda Felix Sønslien // E-mail: odafs1993@gmail.com //Mobile: 90109590

Help define gene panel

The Norwegian Research Council-financed project NCGC are joining forces with Norwegian Cancer Registry to establish a research platform for tumor-profiling in recruiting patients for clinical trials.

The objective is to make Norway an even more attractive location for the industry and to meet the industries specific needs. The first step in this work is to define a gene panel. In this connection the project team wants to get in contact with Oslo Cancer Cluster members who can give feedback on what targets should be included.

For more information, please contact:

More about NCGC here: cancergenomics.no 

Inven2 tildelt 6 millioner i presåkornmidler

I sterk konkurranse fra 45 søkere har Inven2 fått tildelt NOK 6 mill av presåkornpotten for 2016 fra Innovasjon Norge.

− Presåkornmidlene betyr at vi får mobilisert privat kapital til selskaper som har lovende teknologi men hvor det er tidlig i utviklingen av teknologien, og risikoen er høy, sier daglig leder i Inven2 Ole Kristian Hjelstuen.

− Disse midlene skal ikke bare selskaper som springer ut fra Inven2 ha mulighet til å få tilgang til, men også selskaper som tilhører de nettverkene som støttet opp om søknaden vår. Medio august vil vi gå ut med en utlysning der selskaper kan søke om å få investering fra presåkornmidlene Inven2 har fått tildelt. Det vil bli 4-6 ukers søknadsfrist fra utlysning.

Inven2 fikk også tildelt presåkornmidler fra pilottildelingen i  2015. NOK 3 mill er allerede investert i selskapene Prediagnostics AS, Idia AS og Epiguard AS. Presåkornmidlene bidrar til risikoavlastning slik at nystartede selskaper lettere vil kunne tiltrekke seg kapital fra andre investorer.

 

Les mer om årets tildeling:

– Innovasjon Norge: Deler ut 100 millioner gründerkroner

– Shifter: Slik skal de bruke pengene som strøs over norske gründere

 

 

Åpent debattmøte om helseprioriteringer i fremtiden – Det Norske Videnskaps-Akademi i Bergen

På vegne av Det Norske Videnskaps-Akademi har vi gleden av å invitere til åpent debattmøte om helseprioriteringer i fremtiden 26. oktober kl 18:15 – 20:00, i Auditoriet på Litteraturhuset i Bergen, Østre Skostredet 5-7.

Med bakgrunn i Prioriteringsutvalgets rapport vil debattantene debattere prioriteringer av de begrensede ressursene i norsk helsevesen.

Deltagere:

Ole Frithjof Norheim, leder av Prioriteringsutvalget

Anne Lise Ryel, generalsekretær i Kreftforeningen

Prof. Lars A. Akslen, senterleder i CCBIO

Førsteamanuensis Elisabeth Ivarsflaten

Professor Bertil Tungodden

Det vil også være representanter for Helsedepartementet tilstede på møtet.

Mer informasjon HER
Program HER

Møtet er åpent og inngang gratis og vi setter stor pris på om mailen sirkuleres videre til andre interesserte.

Spørsmål kan rettes til: Geir Olav Løken, Administrativ leder, Centre for Cancer Biomarkers CCBIO, Telefon 55 58 54 36 / 905 18 997

45 MNOK to innovative cancer treatments and diagnostics

The Norwegian Research Council and Norwegian Cancer Society are teaming up to make the results of medical and biotechnical research faster available for cancer patients.

The call on 45 MNOK will be administered through the Research Council’s program for biotechnology (BIOTEK21) and commercialization (FORNY2020).

– This is an exciting and unique collaboration between the Norwegian Cancer Society and the Norwegian Research Council. There is a long way from scientific idea to finished product. The process before the product is on the market and used by many patients are demanding and costly. These funds will provide important impetus to future-oriented Norwegian research. There is enormous potential in research and innovation in health, says the Norwegian Cancer Society General Anne Lise Ryel.

Arvid Hallén, CEO of the Norwegian Research Council agrees:

– I think it can mean much that the Norwegian Cancer Society and the Norwegian Research Council will work together on this. To be successful it is important that we also work closely with Norwegian companies that develop products and services for cancer diagnosis and cancer treatment. Fortunately, we have not only excellent researchers and clinics in health and biomedicine, we also have many companies that have shown that they can develop innovative products and services that can help cancer patients, says Hallén.

Applicants for this call will be commercial players who are affiliated research institutions. The announcement will be available on the Research Council’s website from the end of June and has a deadline of 9 September.

Find more information here:

 

255 MNOK to biomedical research

The Norwegian Research Council recently announced four large investments in biomedical research on a total of 255 MNOK.

Of these investments, 60 MNOK will go to to sequencing and precision medicine, 80 MNOK to national biobanks, 65 MNOK to brain research and 50 MNOK to Norwegian Clinical Research Infrastructure Network.

– This is great news. Biomedical research affects not only a nation’s health, but international competitiveness too, says Ketil F. Widerberg, General Manager in Oslo Cancer Cluster in a comment.

For more information: http://www.forskningsradet.no/no/Nyheter/13_milliarder_til_forskningsutstyr/1254010677263/p1174467583739

850 MNOK to innovation projects

The Norwegian Research Council will grant NOK 850 million to industry innovation projects – the largest grant of its kind in history. Application deadline is October 15, 2014.

The Research Council recently launched a website with all relevant information on this funding scheme.

Ketil Widerberg, General Manager of Oslo Cancer Cluster says: “Funding for the biotech industry is hard to obtain in Norway. This increase in grants will make a difference for the biotech members of the Cluster. I am glad to see that the Government and Research Council support industry driven innovation.”

More funding through BIA
Last year the grant to innovation projects within industry was on 700 million. The increase on 150 MNOK mainly comes from the Government`s strenghtening of the Research Council’s BIA – program. BIA funds industry-oriented research and has no thematic restrictions. Five Oslo Cancer Cluster biotech members obtained funding from the BIA program earlier this year. Read more on this here.

Application deadline is 15 October 2014, but already now, you may send in your project ideas and get feedback on them.

Please read the press release in Norwegian here.